A LinkedIn post from Okami Medical describes the use of its LOBO device in a high‑risk case involving a 28‑year‑old patient at 27 weeks of pregnancy with bilateral pulmonary aneurysms. The content emphasizes urgent, targeted intervention aimed at protecting both maternal and fetal health, with multidisciplinary involvement including continuous fetal monitoring.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, physicians used LOBO‑9 and LOBO‑7 devices to treat feeder arteries on the right side and a LOBO‑7 on the left side, supported by the SENDERO MAX system for LOBO‑7 deployment. The procedure reportedly shut down blood flow to both aneurysms in about two minutes, with three LOBO devices implanted, underscoring a focus on speed and precision in complex vascular scenarios.
For investors, the case example suggests that Okami Medical is positioning LOBO as a capable solution for challenging pulmonary and pregnancy‑associated vascular conditions. Demonstrated utility in such complex settings may support clinical adoption, strengthen relationships with interventional radiologists, and contribute to future revenue growth if translated into broader real‑world use.
The post also indicates potential differentiation for Okami Medical within the interventional radiology and MedTech markets, particularly in critical care and high‑acuity cases. While a single case does not provide statistical evidence of efficacy or safety, repeated visibility of successful procedures could enhance the company’s brand, support reimbursement discussions, and improve its competitive standing over time.